Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$41.08

-0.15 (-0.36%)

07:29
09/06/17
09/06
07:29
09/06/17
07:29

Technical View: Sarepta sharply higher on results of 4053-101 study

The stock was last up over 16.3% to $47.80. At that price next resistance is at $48.73. Support is at $47.17.

  • 06

    Sep

  • 11

    Sep

  • 27

    Sep

SRPT Sarepta
$41.08

-0.15 (-0.36%)

09/05/17
NOMU
09/05/17
NO CHANGE
Target $84
NOMU
Buy
Sarepta shares will start reflecting pipeline in 2018, says Nomura Instinet
Sarepta Therapeutics has indicated it will provide an update on dystrophin data from its Phase 1/2 study of SRP-4053 in patients with Duchenne muscular dystrophy amendable to skipping Exon-53 in Q4, Nomura Instinet analyst Christopher Marai tells investors in a research note. The preclinical data suggest a higher level of skipping efficiency of exon-53 relative to exon-51, "bonding well for the potential data set," the analyst contends. He expects Sarepta's gene-therapy pipeline including micro-dystrophin and GALGT2 programs will start to be reflected in the stock in 2018. The analyst views Sarepta as undervalued and keeps a Buy rating on the shares with an $84 price target.
09/04/17
SBSH
09/04/17
NO CHANGE
Target $28
SBSH
Buy
Congressman supporting approval of PTC's DMD treatment, says Citi
Citi analyst Joel Beatty found comments online from U.S. Congressman Collin Peterson that voice support for approval of PTC Therapeutics' (PTCT) Duchenne muscular dystrophy treatment ataluren, which is also known as Translarna. The document appears to have been posted last Thursday in response to the FDA's request for comments regarding its advisory panel meeting scheduled for September 28, and is written in the form of a speech to be given at the meeting, Beatty told investors Friday night in a research note. The analyst confirmed from the Congressman's office that a legislative assistant plans to read the letter on behalf of Rep. Peterson at the September 28 advisory meeting. The comments mention a constituent of Rep. Peterson's with DMD who will be in the audience and for whom "access to ataluren has allowed him to live and thrive well into his 20s with no side effects," Beatty cites the statement as saying. It added, "The full consideration of ataluren not only fulfills the Congressional intent of FDASIA and the 21st Century Cures Act, but also has the potential to save lives across the nation." Beatty believes political support could play a role in the FDA's review of Translarna. The analyst notes that Sarepta Therapeutics' DMD drug Exondys 51 was approved after favorable political support. Beatty sees $20 of upside potential in PTC shares, with only $3 downside risk, around the FDA panel meeting. The analyst has a Buy rating on the shares with a $28 price target. The stock closed Friday up 18c to $20.93. A positive panel vote will likely lead to FDA approval while a negative vote doesn't necessarily mean the FDA will not approve the drug, Beatty argues. His model assumes a 25% probability of success for Translarna.
08/17/17
JPMS
08/17/17
NO CHANGE
JPMS
JPMorgan lists top SMID Biotechnology picks following Q2 results
Analysts at JPMorgan continue think selectively remains important in the small-to-mid cap Biotechnology space. The analysts listed their favorite ideas in "five key buckets." Amicus (FOLD) is the top long-term pick, Ironwood (IRWD) is the top pick among relative underperformers, Otonomy (OTIC) is the top play for a clinical/binary event, Sarepta (SRPT) is the name to take advantage of the recent share weakness, and Ignyta (RXDX) is the "underfollowed/undervalued" favorite, according to JPMorgan's Biotech team.
07/25/17
PIPR
07/25/17
NO CHANGE
Target $50
PIPR
Overweight
Sarepta now has $620M of cash, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff estimates Sarepta Therapeutics has a pro forma cash position of $620M after issuing 7.65M shares at $42.50. The analyst reiterates an Overweight rating on the shares with a $50 price target.

TODAY'S FREE FLY STORIES

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:48
11/22/17
11/22
07:48
11/22/17
07:48
Downgrade
Cytokinetics rating change  »

Cytokinetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

07:46
11/22/17
11/22
07:46
11/22/17
07:46
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:45
11/22/17
11/22
07:45
11/22/17
07:45
General news
U.S. MBA mortgage market index rose 0.1% »

U.S. MBA mortgage market…

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$139.23

2.31 (1.69%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Technical Analysis
Technical View: Deere at new 52-week high after results beat expectations »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

CRM

Salesforce

$108.80

1.43 (1.33%)

07:42
11/22/17
11/22
07:42
11/22/17
07:42
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:40
11/22/17
11/22
07:40
11/22/17
07:40
General news
Treasury Market Outlook: longer dated bond yields are modestly higher »

Treasury Market Outlook:…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Technical Analysis
Technical View: Axalta Coating up on Nippon Paint takeover talks »

The company earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.44 (1.34%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Recommendations
Salesforce analyst commentary  »

Canaccord has 'no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

OSUR

OraSure

$16.55

2.59 (18.55%)

07:36
11/22/17
11/22
07:36
11/22/17
07:36
Recommendations
OraSure analyst commentary  »

OraSure contract win…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.73

0.29 (1.76%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Technical Analysis
Technical View: GameStop trades higher after earnings and outlook »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$14.67

0.15 (1.03%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Recommendations
Nuance analyst commentary  »

In-line guidance likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AAPL

Apple

$173.14

3.16 (1.86%)

, BAC

Bank of America

$26.73

-0.01 (-0.04%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$173.14

3.16 (1.86%)

BAC

Bank of America

$26.73

-0.01 (-0.04%)

MU

Micron

$49.40

1.76 (3.69%)

T

AT&T

$34.33

-0.31 (-0.89%)

ORCL

Oracle

$48.63

-0.39 (-0.80%)

AKS

AK Steel

$4.85

0.22 (4.75%)

PG

Procter & Gamble

$88.72

0.45 (0.51%)

TRIP

TripAdvisor

$32.81

2.33 (7.64%)

PEP

PepsiCo

$116.05

1.14 (0.99%)

PAGP

Plains GP Holdings

$20.48

-0.41 (-1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 29

    Nov

  • 19

    Dec

EKSO

Ekso Bionics

$4.13

1.21 (41.44%)

07:33
11/22/17
11/22
07:33
11/22/17
07:33
Technical Analysis
Technical View: Ekso Bionics trades sharply higher, edging 52-week high »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$30.20

0.5 (1.68%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Initiation
Nutanix initiated  »

Nutanix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 07

    Dec

  • 12

    Dec

HPE

HP Enterprise

$14.12

0.03 (0.21%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Recommendations
HP Enterprise analyst commentary  »

HP Enterprise CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 11

    Dec

GE

General Electric

$17.83

-0.15 (-0.83%)

, DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

07:30
11/22/17
11/22
07:30
11/22/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$17.83

-0.15 (-0.83%)

DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

ROST

Ross Stores

$72.67

-0.07 (-0.10%)

ILG

ILG

$28.11

-0.5 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 12

    Dec

DLTR

Dollar Tree

$99.46

2.35 (2.42%)

07:29
11/22/17
11/22
07:29
11/22/17
07:29
Recommendations
Dollar Tree analyst commentary  »

Dollar Tree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:28
11/22/17
11/22
07:28
11/22/17
07:28
General news
Futures above fair value ahead of holiday »

Stock futures are…

SHOO

Steven Madden

$39.80

-0.6 (-1.49%)

07:28
11/22/17
11/22
07:28
11/22/17
07:28
Conference/Events
Steven Madden management to meet with Buckingham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

BURL

Burlington Stores

$104.94

-1.61 (-1.51%)

07:25
11/22/17
11/22
07:25
11/22/17
07:25
Recommendations
Burlington Stores analyst commentary  »

Burlington Stores price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLH

Red Lion Hotels

$8.55

0.1 (1.18%)

07:24
11/22/17
11/22
07:24
11/22/17
07:24
Conference/Events
Red Lion Hotels management to meet with Craig Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 06

    Dec

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

07:24
11/22/17
11/22
07:24
11/22/17
07:24
Recommendations
TiVo, Comcast, Comcast analyst commentary  »

TiVo ITC win raises odds…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$184.15

1.81 (0.99%)

07:22
11/22/17
11/22
07:22
11/22/17
07:22
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTI

Pluristem

$1.51

0.05 (3.42%)

07:20
11/22/17
11/22
07:20
11/22/17
07:20
Conference/Events
Pluristem management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.